International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
Use in newly diagnosed CLL patients
The CLL‑IPI stratifies CLL patients into four risk groups using age, stage, TP53 status, IGHV status, and β2‑microglobulin to predict survival.
사용 적응증
Identifies prognosis at diagnosis or before first‑line therapy to stratify overall survival and time‑to‑first‑treatment in untreated CLL, including early‑stage disease. Guides watch‑and‑wait vs early‑intervention trial enrollment and highlights patients needing targeted agents when TP53‑aberrant. Robustly validated across >3,500 patients with strong OS/PFS discrimination 1 [Level I evidence] and confirmed in contemporary cohorts 2 [Level I evidence].
통찰 및 주의사항
Stratifies risk using age, stage, TP53 status, IGHV status, and β2‑microglobulin, predicting survival and time‑to‑first‑treatment. Validated across >3000 patients with c‑statistic ~0.72 for OS 1 [Level I evidence]. Retains prognostic value with targeted agents for PFS but less for OS 2 [Level II evidence]. Use cautiously: very‑high‑risk group overlap, diminished discrimination in novel‑therapy era, and does not guide treatment selection.